ACCRUED EXPENSES

12 Months Ended

Dec. 31, 2021

Payables and Accruals [Abstract]

ACCRUED EXPENSES

ACCRUED EXPENSES

Accrued expenses consist of the following (in thousands):

	December 31,
	2021		2020
Accrued selling, general and administrative expenses	$	12,063	$	23,288
Accrued research and development expenses	5,480		6,682
Other accrued operating expenses	14,912		11,196
Compensation and benefits	45,491		22,202
Accrued royalties (1)	35,298		3,040
Accrued interest	5,358		2,376
Product returns and wholesaler service fees	8,953		2,190
Total	$	127,555	$	70,974

(1) At December 31, 2021, accrued royalties included a $32.0 million milestone payment to Skyepharma that was met in the fourth quarter of 2021 for achieving annual net sales collected of $500.0 million on the Company’s DepoBupivacaine products, including EXPAREL. This milestone was subsequently paid in the first quarter of 2022. See Note 9, Goodwill and Intangible Assets, for more information.